A5022845423- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Gastric Cancer Management and Outcomes
- Protease and Inhibitor Mechanisms
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Cancer-related molecular mechanisms research
- Molecular Biology Techniques and Applications
- Urinary and Genital Oncology Studies
- Adenosine and Purinergic Signaling
- Cancer, Hypoxia, and Metabolism
- Growth Hormone and Insulin-like Growth Factors
- Plant-derived Lignans Synthesis and Bioactivity
- Ferroptosis and cancer prognosis
- Radiopharmaceutical Chemistry and Applications
- RNA modifications and cancer
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Neuroblastoma Research and Treatments
- Eicosanoids and Hypertension Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Metabolism, Diabetes, and Cancer
Gilead Sciences (United States)
2017-2024
Bristol-Myers Squibb (Switzerland)
2013
University of California, San Francisco
2007-2008
UCSF Helen Diller Family Comprehensive Cancer Center
2008
San Francisco State University
2007
University of California San Francisco Medical Center
2005
Background Cluster of differentiation (CD)73-adenosine and transforming growth factor (TGF)-β pathways are involved in abrogated antitumor immune responses can lead to protumor conditions. This Phase 1 study ( NCT03954704 ) evaluated the safety, pharmacokinetics, pharmacodynamics, efficacy dalutrafusp alfa (also known as GS-1423 AGEN1423), a bifunctional, humanized, aglycosylated immunoglobulin G1 kappa antibody that selectively inhibits CD73-adenosine production neutralizes active TGF-β...
Background Matrix metalloproteinase-9 (MMP9) selectively cleaves extracellular matrix proteins contributing to tumor growth and an immunosuppressive microenvironment. This study evaluated andecaliximab (ADX), inhibitor of MMP9, in combination with nivolumab (NIVO), for the treatment advanced gastric cancer. Methods Phase 2, open-label, randomized multicenter evaluating efficacy, safety, pharmacodynamics ADX+NIVO versus NIVO patients pretreated metastatic or gastroesophageal junction (GEJ)...
Abstract In breast and certain other cancers, receptor tyrosine kinases, including the insulin-like growth factor I (IGF-IR), play an important role in promoting oncogenic process. The IGF-IR is therefore target for developing new anti–breast cancer therapies. An initial screening of a chemical library against cells identified diaryl urea compound as potent inhibitor signaling. This class compounds has not been studied inhibitors IGF-IR. We effectiveness one compound, PQ401, at antagonizing...
Abstract We have reported that nordihydroguaiaretic acid (NDGA) inhibits the tyrosine kinase activities of IGF‐1 receptor (IGF‐1R) and HER2 in breast cancer cells. Herein, we studied effects NDGA on growth estrogen (ER) positive MCF‐7 cells engineered to overexpress (MCF‐7/HER2‐18). These are an vitro model HER2‐driven, ER positive, tamoxifen resistant cancer. was equally effective at inhibiting both parental MCF‐7/HER2‐18 Half maximal for cell lines were 10–15 µM range. The inhibitory...
Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) Trop-2-directed antibody drug conjugate with hydrolysable linker and potent SN-38 payload. This study explored Trop-2 expression tumors treated SG cohorts 1 to 3 (C1-3) from the TROPHY-U-01 evaluated whether efficacy was associated expression.
Matrix metalloproteinase 9 (MMP9) expression in the tumor microenvironment is implicated multiple protumorigenic processes. Andecaliximab (GS-5745), a monoclonal antibody targeting MMP9 with high affinity and selectivity, was evaluated combination gemcitabine nab-paclitaxel patients advanced pancreatic adenocarcinoma.This phase I study completed two parts: part A dose-finding, monotherapy that enrolled solid tumors, B examined andecaliximab chemotherapy specific patient cohorts. In cohort of...
Background Matrix metalloproteinase 9 (MMP9) is implicated in protumorigenic processes. Targeting either stromal or epithelial MMP9 reduces the incidence of metastasis. Andecaliximab a monoclonal antibody that targets with high affinity and selectivity. However, no study has examined whether inhibition T-cell programmed death 1 (PD-1) presence andecaliximab increases activated lymphocyte infiltration into tumor, thereby increasing antitumor activity more than anti-PD-1 monotherapy. In this...
Abstract BACKGROUND Nordihydroguaiaretic acid (NDGA) is an inhibitor of the IGF‐1 receptor (IGF‐1R) in breast and other cancers, concomitantly inhibits tumor growth both cultured cells animals. The current study evaluates effect NDGA on androgen‐stimulated human prostate cancer cells. METHODS LAPC‐4 tissue culture were androgen starved for 3 days, 1 nM dihydrotestosterone (DHT) androgens then added up to 7 cell proliferation measured. IGF‐1R protein expression was measured by Western blot,...
15500 Background: NDGA is a butanediol with effects on tumor cells, including inhibition of insulin growth factor receptor (IGF-1R) autophosphorylation. In vitro studies suggest that attenuates androgen-mediated prostate cancer without competitive androgen blockade. Its PSA in pts were studied. Methods: Eligible included men recurrent following definitive local therapy rising and no metastasis. Both dependent (PSA normal tesosterone - ADPC) independent castrate level testosterone AIPC) was...
Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9), an extracellular enzyme involved in remodeling, tumor growth, and metastasis. In preclinical models, MMP9 inhibitors have been shown to enhance the cytotoxic effects of chemotherapeutic agents suppress distant this phase Ib, multicenter study, safety efficacy ADX combined with S-1 plus cisplatin (SP) or oxaliplatin (SOX) as first-line treatment were evaluated Japanese patients advanced gastric...
58 Background: Cancer is characterized by continuous remodeling of the extracellular matrix (ECM) through a process degradation and replacement ECM components, such as collagens. Matrix-metalloproteinase 9 (MMP9) involved in this its inhibition hypothesized to reduce turnover. MMP9 expression limited healthy tissues, but high tumor epithelia, infiltrating inflammatory cells fibroblasts. Collagen I III fragments (neoepitopes C1M C3M) blood may provide measure MMP activity (BMC 13:554. 2013)....
Abstract Although gastric cancer (GC) may be classified into molecular subtypes based on the TCGA 1 or ACRG 2 classification, tumor immune microenvironment (TME) remains under-evaluated in both systems. Using unsupervised clustering of gene expression signatures that describe TME composition and properties malignant cells from an integrated collection 11 public cohorts, we identified five TME-based GC subtypes: mesenchymal (Mes), fibrotic (F), immune-enriched (IE), B-cell inflamed (BI),...
<p>Table S1 and Table S2</p>
<div>AbstractPurpose:<p>Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) Trop-2–directed antibody drug conjugate with hydrolysable linker and potent SN-38 payload. This study explored Trop-2 expression tumors treated SG cohorts 1 to 3 (C1–3) from the TROPHY-U-01 evaluated whether efficacy was associated expression.</p>Patients Methods:<p>TROPHY-U-01 (NCT03547973) an open-label phase...
<div>AbstractPurpose:<p>Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) Trop-2–directed antibody drug conjugate with hydrolysable linker and potent SN-38 payload. This study explored Trop-2 expression tumors treated SG cohorts 1 to 3 (C1–3) from the TROPHY-U-01 evaluated whether efficacy was associated expression.</p>Patients Methods:<p>TROPHY-U-01 (NCT03547973) an open-label phase...
<p>Table S1 and Table S2</p>
<p>Table S1 and Table S2</p>
<div>AbstractPurpose:<p>Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) Trop-2–directed antibody drug conjugate with hydrolysable linker and potent SN-38 payload. This study explored Trop-2 expression tumors treated SG cohorts 1 to 3 (C1–3) from the TROPHY-U-01 evaluated whether efficacy was associated expression.</p>Patients Methods:<p>TROPHY-U-01 (NCT03547973) an open-label phase...
<p>Table S1 and Table S2</p>
137 Background: Matrix metalloproteinase 9 (MMP9) is a poor prognostic factor in gastric cancer. Preclinical studies suggest that MMP9 inhibition can relieve immune suppression, promote T cell infiltration, and potentiate benefits of checkpoint blockade. ADX monoclonal antibody inhibits the enzymatic activity MMP9. In this study, safety, PK, exploratory biomarkers, preliminary efficacy alone combination with nivo were assessed. Methods: Up to 6 Japanese subjects be enrolled Cohort 1...
Clinical tumor tissues that are preserved as formalin-fixed paraffin-embedded (FFPE) samples result in extensive cross-linking, fragmentation, and chemical modification of RNA, posing significant challenges for RNA-seq-based gene expression profiling. This study sought to define an optimal RNA-seq protocol FFPE samples. We employed a common RNA extraction method then compared library preparation protocols including RNAaccess, RiboZero PolyA terms sequencing quality concordance using...
101 Background: Andecaliximab (andeca) is a monoclonal antibody that selectively inhibits matrix metalloproteinase 9 (MMP9). IL-7 enhances the proliferation and survival of naïve, memory, effector T-cells (but not regulatory T-cells) in periphery. Previous clinical trials with systemic recombinant therapy increased TCR diversity. In disease setting, elevated circulating may be due to compensatory increase production as demonstrated mice upon inhibition signaling. Methods: An vitro screen,...